OPEN END TURBO CALL WARRANT - AMGEN | Real-time Boerse Frankfurt Warrants 01:52:24 04/07/2024 pm IST | ||
| 1.72 EUR | -0.58% |
|
| Current month | -4.42% | ||
| 1 month | +1.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 1.72 | -0.58% |
| 03/24/03 | 1.73 | -2.81% |
| 02/24/02 | 1.78 | -0.56% |
| 01/24/01 | 1.79 | -1.10% |
| 28/24/28 | 1.81 | +0.56% |
Real-time Boerse Frankfurt Warrants
Last update July 04, 2024 at 01:52 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | UBS |
| WKN | UH4X6F |
| ISIN | DE000UH4X6F2 |
| Date issued | 03/12/2021 |
| Strike | 120.1 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.8 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.95 € |
|---|---|
| Lowest since issue | 0.77 € |
| Spread | 0.1 € |
| Spread % | 5.49% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
309.4
USD
Average target price
316.4
USD
Spread / Average Target
+2.28%
- Stock Market
- Certificates
- Certificat
